N/A N=219 HIV-Tb Confections Among HIV Patients
HIV
Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=30 HIV-related Insomnia and Inflammation
Hiv · Insomnia
Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607
N/A N=114 Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 1 N=11 Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection
HIV INFECTIONS
Primary: Numbers of Treatment Related Side Effects (DLT = Reaction 3 or More) — 0; 0 side effects
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
N/A N=37 Cardiovascular Prevention for Persons With HIV
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
N/A N=300 HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 2 N=128 Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women
HIV Infections · H1N1 Influenza Virus
Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 118; 11; 8; 0 Participants
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
N/A N=282,368 Kaiser Permanente HIV Cohort Study
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
Phase 2 N=251 HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Infection, Human Immunodeficiency Virus
Primary: Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24 — 80; 69; 76; 72 Percentage of Participants
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
Phase 2 N=36 HIV and Fat Accumulation
HIV Infection
Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2
N/A N=20 Poor Sleep and Inflammation in HIV-Infected Adults
HIV-1-infection · Sleep Deprivation · Inflammation
Primary: Soluble CD14 — 1290; 1196 ng/mL
N/A N=42 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
HIV Infections
Primary: Combined Endpoint Including HIV RNA and HIV DNA — 0; 0 Participants
N/A N=114 Analytical Treatment Interruption in HIV Positive Patients
HIV-1 Infection
Primary: Assessment of the Number of Participants With a HIV Plasma Viral Load Below the Lower Limit of Detection 48 Weeks Following Interruption of Antiretroviral Treatment — 0…
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
N/A N=9,572 HIV Screening in the Emergency Department Setting
HIV Infections
Primary: Percentage of Tested Participants Newly Diagnosed as HIV Infected — 6; 3 percentage of tested that are positive
Phase 2 N=395 Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Herpes Zoster · HIV Infections
Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Phase 4 N=43 Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
HIV
Primary: ZDV-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject — 33.89; 29.7 pmol/10^6 cells
Phase 2 N=150 Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infections, Papillomavirus
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms — 46; 18; 19; 2 Participants
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
N/A N=176 Post-release Retention in HIV Care for Ex-inmates in South Africa
Hiv · Adherence, Patient
Primary: Number of Participants in Care at Six Months — 67; 19 Participants